TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.

Irene Marafini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.